Preadmission Metformin Use Is Associated with Reduced Mortality in Patients with Diabetes Mellitus Hospitalized with COVID-19
et al., Journal of General Internal Medicine, doi:10.1007/s11606-024-08864-x, Sep 2024
Metformin for COVID-19
3rd treatment shown to reduce risk in
July 2020, now with p < 0.00000000001 from 107 studies.
Lower risk for mortality, ventilation, ICU, hospitalization, progression, recovery, and viral clearance.
No treatment is 100% effective. Protocols
combine treatments.
6,300+ studies for
210+ treatments. c19early.org
|
Retrospective 11,993 hospitalized COVID-19 patients with diabetes mellitus but without chronic kidney disease or need for hemodialysis, showing lower mortality with metformin use.
Standard of Care (SOC) for COVID-19 in the study country,
the USA, is very poor with very low average efficacy for approved treatments1.
Only expensive, high-profit treatments were approved for early treatment. Low-cost treatments were excluded, reducing the probability of early treatment due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments.
|
risk of death, 18.0% lower, RR 0.82, p < 0.001, treatment 4,667, control 5,745, propensity score weighting.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Harmon et al., 19 Sep 2024, retrospective, USA, peer-reviewed, 6 authors, study period 25 January, 2020 - 9 February, 2022.
